title: Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas.
abstract: The goal of this study was to evaluate the mechanism of cyclodextrin-based nanoparticle (CDP-NP) uptake into a murine glioma model. Using mixed in vitro culture systems, we demonstrated that CDP-NPs were preferentially taken up by BV2 and N9 microglia (MG) cells compared with GL261 glioma cells. Fluorescent microscopy and flow cytometry analysis of intracranial GL261 gliomas confirmed these findings and demonstrated a predominant CDP-NP uptake by macrophages (MPs) and MG within and around the tumor site. Notably, in mice bearing bilateral intracranial tumor, MG and MPs carrying CDP-NPs were able to migrate to the contralateral tumors. In conclusion, these studies better characterize the cellular distribution of CDP-NPs in intracranial tumors and demonstrate that MPs and MG could potentially be used as nanoparticle drug carriers into malignant brain tumors.
  
  
  BACKGROUND
  The goal of this study was to evaluate the mechanism of cyclodextrin-based nanoparticle (CDP-NP) uptake into a murine glioma model. CDP-NP was preferentially taken up microglia (MG) cells as compared to glioma cells. A predominant CDP-NP uptake by macrophages and MG was also shown in and around the tumor site. Macrophages and MG could potentially be used as nanoparticle drug carriers into malignant brain tumors.
authors.affiliation: Division of Neurosurgery, City of Hope National Cancer Center, Duarte, California, USA.
authors.forename: Darya
authors.initials: D
authors.lastname: Alizadeh
authors.forename: Leying
authors.initials: L
authors.lastname: Zhang
authors.forename: Jungyeon
authors.initials: J
authors.lastname: Hwang
authors.forename: Thomas
authors.initials: T
authors.lastname: Schluep
authors.forename: Behnam
authors.initials: B
authors.lastname: Badie
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D003505:Cyclodextrins / Q000737:chemistry* / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000737:chemistry*; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry* / Q000627:therapeutic use
chemical_list: D003505:Cyclodextrins; D004337:Drug Carriers